Materials and methods
All manipulations requiring anhydrous conditions were carried out in flame-dried glassware, with magnetic stirring and under a nitrogen atmosphere. All commercially available reagents were used as received.
Anhydrous solvents were purchased from commercial sources and withdrawn from the container by syringe, under a slight positive pressure of nitrogen. The reactions were monitored by analytical thin-layer chromatography (TLC) using silica gel 60 F 254 pre-coated glass plates (0.25 mm thickness). Visualization was accomplished by irradiation with a UV lamp and/or staining with a potassium permanganate alkaline solution, ninhydrin or ceric ammonium molibdate solution. Flash column chromatography was performed according to the method of Still and co-workers [1] using Chromagel 60 ACC (40-63 µm) silica gel.
Automated chromatography was performed with Grace Reveleris instrument. Proton NMR spectra were recorded on a spectrometer operating at 400. ESI-MS spectra were recorded on the ion trap mass spectrometer Finnigan LCQ Advantage or Micro Waters Q-Tof (ESI source). The MALDI-TOF-MS spectra were recorded on the instrument Bruker Microflex™ LT, supporting the sample on the 2,5-dihydroxybenzoic acid (DHB), α-cyano-4-hydroxycinnamic acid (HCCA) and sinapinic acid (SIN) matrices. The peptide calibration standard (300-3000 Da range), which consisted of Angiotensin II, Angiotensin I, Substance P, Bombesin; ACTH clip 1-17, ACTH clip 18-39, Somatostatin 28, was purchased from Bruker Daltonics® and used to calibrate the MALDI-TOF-MS instrument. The sample was mixed in equal volumes with the matrix solution: a small amount (1 μL) of this mixture was spotted on the target surface. The target matrix was dried at room temperature and then analyzed. Procedure for freeze-drying. The product was dissolved in water and frozen with dry ice; the freeze-drying was carried out at least for 48 h at -50 °C using the instrument 5Pascal Lio5P DGT. The cytotoxicity of MMAE (1 was added to each well and cells were incubated for another 2 hour period. Finally, 100 µL of lysis buffer (10% SDS, 10 mM HCl) were added, and cells placed in the incubator overnight for the formazan crystal solubilization. Absorbance at 540 nm was measured using FLUOstar Omega (BMG Labtech) instrument and the growth inhibition ratio was calculated. Blank controls detecting cell-free media absorbance were performed in parallel. Three experimental replicates were used. The half-maximal inhibitory concentration values (IC 50 ) were obtained from viability curves using GraphPad Prism 6. The cell viability was expressed as percentage relative to the respective control conditions (0.1% of DMSO).
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Synthesis of Integrin ligand-VA-MMAE/MMAF conjugates (7-8, 11-12)
Scheme S1. 
Synthesis of cleavable conjugates cyclo[DKP-RGD]-PEG-4-Val-Ala-MMAE (7), cyclo[DKP-isoDGR]-PEG-4-Val-Ala-MMAE (8), cyclo[DKP-RGD]-PEG-4-Val-Ala-MMAF (11) and cyclo[DKP-isoDGR]-PEG-4-Val-Ala-MMAF (12). REAGENTS AND CONDITIONS:
4-Pentynoyl-Val-Ala-PABA (16)
Fmoc-Val-Ala-PABA 15 (800 mg, 1.55 mmol, 1 eq.), prepared as previously reported, [2] was dissolved in DMF (20 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C and piperidine (766 μL, 7.75 mmol, 5 eq.) was added. The reaction was stirred at room temperature for 2 h. The mixture was concentrated at reduced pressure and used directly, without any further purification, in the next step. 
4-Pentynoyl-Val-Ala-PABC-PNP (17)
A solution of compound 16 in dry THF (78 mL) was cooled to 0 °C under nitrogen atmosphere. Pyridine (270 μL, 3.33 mmol, 2.5 eq.) and 4-nitrophenylchloroformate (537 mg, 2.66 mmol, 2 eq.) were added, then the mixture was warmed up to room temperature and stirred for 2 h. The reaction mixture was then concentrated under reduced pressure, EtOAc (50 mL) was added and the solution was washed with a 1 M aqueous solution of KHSO 4 (3 × 20 mL) and brine (20 mL). The organic phase was dried and concentrated, then the crude product was purified by flash chromatography 
4-Pentynoyl-Val-Ala-PABC-MMAF (19)
Compound 17 (20 mg, 0.037 mmol, 1 eq.) and HOBt (3 mg, 0.019 mmol, 0.5 eq.) were dissolved in dry DMF under argon atmosphere. Commercially available MMAF·TFA (37 mg, 0.044 mmol, 1.2 eq.) was dissolved in dry DMF:Pyridine (4:1, 600 µL, reaction total volume) containing DIPEA (12 µL, 0.066 mmol, 1.8 eq.), and added to the solution of compound 17 at 0 ºC. Then, the mixture was allowed to reach room temperature and stirred 65 h under argon atmosphere. ; found: 684.360.
Cyclo[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAE (8)
Alkyne 18 (3 mg, 2.7 µmol, 1 eq.) was dissolved in 500 µL of dry DMF and added to a solution of cyclo [DKP-isoDGR] 
cyclo[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAF (12)
Alkyne 19 (3.5 mg, 3 µmol, 1 eq.) was dissolved in 500 µL of dry DMF and added to a solution of cyclo [DKP-isoDGR] -PEG-4-N 3 21 [4] (4.5 mg, 4.5 µmol, 1.5 eq.) in 500 µL of degassed water, under nitrogen atmosphere. Sodium ascorbate (0.3 mg, 1.5 µmol, 0.5 eq.) and CuSO 4 ·5H 2 O (0.3 mg, 1 µmol, 0.3 eq.) were added to the solution and the mixture was stirred overnight at room temperature. Volatiles were removed under reduced pressure and the residue was purified by semipreparative HPLC (gradient: from 95% (H 2 O + 0.1% CF 3 COOH) / 5% (CH 3 CN + 0.1% CF 3 COOH) to 20% (H 2 O + 0.1% CF 3 COOH) / 80% (CH 3 CN + 0.1% CF 3 COOH) in 17 min, t R product = 11.5 min). The collected fractions were concentrated under reduced pressure and freeze-dried from 1:1 water/CH 3 CN to afford the desired product 12 as a white solid (2.8 mg, 45% yield). 
MS (ESI+)
:
Synthesis of Integrin ligand-Unc-MMAE/MMAF conjugates (9-10, 13-14) Scheme S2. Synthesis of uncleavable conjugates: cyclo[DKP-RGD]-PEG-4-MMAE (9), cyclo[DKP-isoDGR]-PEG-4-MMAE (10), cyclo[DKP-RGD]-PEG-4-MMAF (13) and cyclo[DKP-isoDGR]-PEG-4-MMAF (14). REAGENTS AND CONDITIONS:
4-Pentynoyl-MMAE (22)
A solution commercially available 4-pentynoic acid (4.2 mg, 0.042 mmol, 1.5 eq.) in dry DMF (0.5 mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (19 mg, 0.048 mmol, 1.7 eq.), HOAt (7 mg, 0.048 mmol, 1.7 eq.) and iPr 2 NEt (20 µL, 0.112 mmol, 4 eq.) were added and the mixture was stirred for 20 min at 0 °C. A solution of commercially available MMAE in dry DMF (1 mL) was added to the stirred mixture. The reaction was allowed to slowly reach room temperature and stirred overnight. The mixture was diluted with EtOAc (30 mL), washed with 1 M aqueous solution of KHSO 4 (2 × 10 mL) and brine (1 × 20 mL 
4-Pentynoyl-MMAF (23)
Commercially available 4-pentynoic acid (3.5 mg, 0.036 mmol, 1.5 eq.) in dry DMF (0.4 mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (16 mg, 0.041 mmol, 1.7 eq.), HOAt (6 mg, 0.041 mmol, 1.7 eq.) and iPr 2 NEt (21 µL, 0.120 mmol, 5 eq.) were added and the mixture was stirred for 20 min at 0 °C. A solution of commercially available MMAF·TFA in dry DMF (1 mL) was added to the stirred mixture. The reaction was allowed to slowly reach room temperature and stirred overnight. 
